-
Dangote to launch $16bn refinery in Kenya
-
Nagoya mayor says sorry for Asian Games 'inconveniences'
-
North Korean leader 'extremely obese': Seoul spy agency
-
G20 trade officials meet under shadow of tariffs, overcapacity
-
Yankees and pope-backed White Sox start MLB playoffs with wins
-
India's fat dog vote goes viral
-
Malaysia's ex-PM Mahathir in hospital for observation
-
Asian Games crowds in spotlight as 998 see hosts in 50,000 stadium
-
'No limits': Marathon world record holder Sawe chasing history
-
The eight stadiums for the 2027 Rugby World Cup
-
Countdown begins to biggest-ever Rugby World Cup
-
Thieves swipe drugs under nose of Fiji police, swap with flour
-
Bangladesh women lose ground after quota reform
-
South Korea demands North apologise for DMZ mine blasts
-
Vietnam admits 'differing opinions' on Hanoi development
-
In Nepal's flood zone, teachers mourn students who never returned
-
Stocks temper gains as oil pares heavy losses, US data in focus
-
US Supreme Court lifts limits on third-country deportations
-
New Zealand denies breaching climate commitments to EU
-
Antonelli eager to 're-establish order' as F1 returns to Malaysia
-
Albert becomes youngest US scorer in 4-2 win over Chile
-
Paw-fect candidate: Australia finds new koala rescue dog
-
Pirate island's plunging population shows Greece's demographic decline
-
One third of world population exposed to harmful air pollution: monitor
-
With elections ahead, Latvia's Russian-speakers reject Moscow's help
-
North Korea denies South's claim it was apparently behind DMZ mine blasts
-
Brazil football clubs face massive sponsorship blow from betting ban
-
West Bank's violent settlers part of a new generation fuelled by ideology
-
ChatGPT maker wants to be the App Store for AI as safety concerns grow
-
US-led coalition ends mission in Iraq
-
Women fight fires and sexism in Indonesian Borneo
-
Pope-backed White Sox join Braves with MLB playoff wins
-
Forsling's OT blast lifts Florida over Carolina in NHL opener
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 30
-
Alpha Growth Management Opens Rep Office in Japan
-
Guardian Metal Resources PLC Announces Total Voting Rights
-
NBA close to picking new $12-13bn Vegas team owners: report
-
Hurricane Polo sweeps over Mexico's Pacific coast, heads inland
-
LA28 Olympics torch relay to visit all 50 states
-
Grynspan pulls ahead in race to lead UN: diplomat
-
Spain brush aside Croatia in Nations League, England down Czechs
-
Trump touts AI boss pledge to self-regulate
-
Trump hails 'morally binding' AI self-regulation pledge
-
Oil down, but stocks lower as bond yields rise
-
Yamal inspires Spain to Croatia romp on World Cup homecoming
-
England break down stubborn Czechs to claim first Nations League win
-
UN to hold fourth informal poll of secretary-general candidates
-
UN Security Council extends Haiti anti-gang force by 6 months
-
Who are the Emiratis behind crisis-hit Manchester City?
-
Manchester City guilty of Premier League charges: What comes next?
UK researchers cure man who had Covid for 411 days
British researchers announced Friday they have cured a man who was continually infected with Covid for 411 days by analysing the genetic code of his particular virus to find the right treatment.
Persistent Covid infection -- which is different to long Covid or repeated bouts of the disease -- occurs in a small number of patients with already weakened immune systems.
These patients can test positive for months or even years with the infection "rumbling along the whole time", said Luke Snell, a physician specialising in infectious diseases at Guy's and St Thomas' NHS Foundation Trust.
The infections can pose a serious threat because around half of patients also have persistent symptoms such as lung inflammation, Snell told AFP, adding that much remains unknown about the condition.
In a new study published in the journal Clinical Infectious Diseases, a team of researchers at Guy's and St Thomas' NHS Foundation Trust and King's College London describe how a 59-year-old man finally overcame his infection after more than 13 months.
The man, who has a weakened immune system due to a kidney transplant, caught Covid in December 2020 and continued to test positive until January this year.
To discover whether he had contracted Covid numerous times or if it was one persistent infection, the researchers used a rapid genetic analysis with nanopore sequencing technology.
The test, which can deliver results in as little as 24 hours, showed the man had an early B.1 variant which was dominant in late 2020 but has since been replaced by newer strains.
Because he had this early variant, the researchers gave him a combination of the casirivimab and imdevimab monoclonal antibodies from Regeneron.
Like most other antibody treatments, the treatment is no longer widely used because it is ineffective against newer variants such as Omicron.
But it successfully cured the man because he was battling a variant from an earlier phase of the pandemic.
- Resistant to treatment -
"The very new variants that are increasing in prevalence now are resistant to all the antibodies available in the UK, the EU and now even the US," Snell said.
The researchers used several such treatments to try to save a seriously ill 60-year-old man in August this year who had been infected since April.
However none worked.
"We really thought he was going to die," Snell said.
So the team crushed up two antiviral treatments not previously used together -- Paxlovid and remdesivir -- and administered them to the unconscious patient via a nasal tube, according to a non-peer-reviewed preprint study on the website ResearchSquare.
"Miraculously he cleared and perhaps this is now the avenue for how we treat these very difficult persistent infections," Snell said, emphasising that this treatment may not translate for normal Covid cases.
At the ECCMID conference in April, the team announced the longest-known persistent infection in a man who tested positive for 505 days before his death.
That "very sad case" came earlier in the pandemic, Snell said, adding that he was grateful there were now so many more treatment options available.
G.P.Martin--AT